Benzinga | Jul 8, 2021 06:02AM EDT

Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02

* New clinical data demonstrates antitumor effect of EVX-01 in combination with anti-PD1 treatment

* Objective Response Rate (ORR) of 67% with EVX-01 + anti-PD1 treatment in nine metastatic melanoma patients, including 22% Complete Response (CR) and 44% Partial Response (PR)

* Clinical trial data supports the proprietary AI-Immunology platform, PIONEER, with regard to: neoepitope prediction, de novo T-cell activation and clinical response in cancer patients

* Phase 2 trial of EVX-01 in melanoma, planned to start in December 2021

* First patients in Phase 1/2a trial of EVX-02 showed T-cell activation, with further data to be generated with aim of initiating Phase 2 trial in Q2 2022

* Conference call and webcast this morning July 8, 2021 at 8:00 AM EDT